Costly Cancer Drug Offers Hope, but Also a Dilemma EXPERIMENTAL TREATMENT After participating in a clinical trial comparing Avastin with another new drug, Gailanne Reeh continued the regimen.Josh Haner/The New York Times It took only an instant for 58-year-old Gailanne Reeh to go from the...
Peripheral Neuropathy Therapy: Findings in peripheral neuropathy therapy reported from University of Californi Findings in peripheral neuropathy therapy reported from University of California, Division of Neuroscience (NewsRx.com) -- A new study, 'Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful...
FDA Approvals: Herceptin, Eloxatin, Extended-Release Venlafaxine HCl Describe the potential benefits of trastuzumab in the adjuvant treatment of human epidermal growth-factor receptor 2positive early breast cancer.Describe long-term survival data from an oxaliplatin clinical trial of patients with stage...
FDA Approvals: Herceptin, Eloxatin, Extended-Release Venlafaxine HCl _ FDA Approvals: Herceptin, Eloxatin, Extended-Release Venlafaxine HCl.
Access Pharma Ties China Clinical Trials to Drug Out-licensing Access Pharmaceuticals, Inc.(ACCP.OB) of Dallas, TX has out-licensed the China rights to ProLindac, its platinum cancer drug currently in Phase II trials, to Jiangsu Aosaikang Pharmaceutical Co., Ltd.
of Nanking [ASK].
ASK will be...
Access Licenses ProLindac(TM) to Jiangsu Aosaikang Pharmaceutical Co., LTD., a Leading Oncology Pharmaceutical 'We are very pleased to have ASK, a leading supplier of platinum based agents inChina, as our first partner for ProLindac,' said Jeffrey B.Davis 'ProLindac is a synergistic product to our current product portfolio, and represents a...
ASCO: Two Minerals May Prevent Neurotoxicity in Colon Cancer Treatment CHICAGO, June 1 -- A mineral infusion may protect against neurotoxicity during oxaliplatin (Eloxatin) -based chemotherapy for colon cancer, although dose schedule likely plays a bigger role, according to two analyses of a clinical trial...
ASCO: Oxaliplatin (Eloxatin) Gives Survival Edge for Colon Cancer CHICAGO, June 1 -- Adding oxaliplatin (Eloxatin) to a standard chemotherapy regimen for stage II or III colon cancer may provide a small five-year survival advantage, according to researchers here.Together with fluorouracil (Adrucil)...
Sanofi-aventis gets US FDA approval for oxaliplatin sNDA Sanofi-aventis announced that the US Food and Drug Administration (FDA) approved the supplemental new drug application (sNDA) to include six-year overall survival analysis from the Mosaic trial in the Eloxatin (oxaliplatin injection)...
New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival - FDA Approval Based on Updated Results Showing a 20% Reduction in the Risk of Death at Six Years and a 22% Improvement of Disease Free Survival at Five Years, For Stage III Colon Cancer, Post Surgery - BRIDGEWATER, N.J., May 28 /PRNewswire...
New Eloxatin (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Da - FDA Approval Based on Updated Results Showing a 20% Reduction in the Risk of Death at Six Years and a 22% Improvement of Disease Free Survival at Five Years, For Stage III Colon Cancer, Post Surgery - BRIDGEWATER, N.J., May 28, 2008 ...
Access Pharmaceuticals Highlighted in Gene Marcial's New Book '7 Commandments of Stock Investing' /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc.announced today that renowned business columnist and author Gene Marcial of BusinessWeek has highlighted Access Pharmaceuticals in his recently released investing book titled '7...
